Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Balance Sheet

v3.21.2
Condensed Consolidated Interim Balance Sheet - USD ($)
$ in Thousands
Sep. 30, 2021
Jun. 30, 2021
Current assets    
Cash and cash equivalents $ 19,339 $ 10,537
Prepaid expenses, deposits and other 769 756
Clinical trial deposit   500
Current assets 20,108 11,793
Clinical trial deposit 2,100 1,600
Property, equipment and intangibles, net 135 150
Total assets 22,343 13,543
Current liabilities    
Accounts payable and accrued liabilities 2,510 2,219
Related party payables 491 561
Current liabilities 3,001 2,780
Milestone payment liability 179 182
Total liabilities 3,180 2,962
Stockholders’ equity    
Common stock Authorized 95,000 shares at March 31, 2021 and June 30, 2020, $0.001 par value 31,764 issued at March 31, 2021 (June 30, 2020 - 11,458) 48 33
Additional paid-in capital 125,074 106,821
Accumulated deficit (119,655) (111,225)
Accumulated other comprehensive income 21 21
Total stockholders’ equity 19,163 10,581
Total liabilities and stockholders’ equity 22,343 13,543
Preferred Stock Series A    
Stockholders’ equity    
Preferred stock 279 279
Preferred Stock Series C    
Stockholders’ equity    
Preferred stock $ 13,396 $ 14,652